US Edition
News from Healio
Media Bias Ratings
Average Bias Rating:
Center
Center
byAd Fontes MediaDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Healio News
Cyber Security · United StatesZIDO SUN // Shutterstock In an ever-evolving landscape of changing technological advances and increasingly sophisticated cybercrime practices, individuals and businesses should remain informed and vigilant regarding the rise of cybersecurity threats and data breaches. Cybercrimes such as phishing, identity theft, business fraud and other methods that criminals use to gain unauthorized access to personal accounts can lead to financial loss as w…See the Story
Cybersecurity threats and data breaches
95% Center coverage: 21 sources
DiabetesNovo Nordisk A/S (NYSE:NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes. The update marks the first evaluation of amycretin in people with type 2 diabetes. Novo Nordisk is planning to initiate a phase 3 development program with amycretin for adults with type 2 diabetes in 2026. In June, the company said it planned to initiate a phase 3 development for amycretin for adults with overweight or obesit…See the Story
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients - Novo Nordisk (NYSE:NVO)
60% Center coverage: 5 sources
